Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

England Unveils £680m Innovative Medicines Fund

Bigger Than Had Been Proposed, Fund Extends Cancer Drugs Fund To Other Treatment Areas

Executive Summary

England’s Innovative Medicines Fund is aimed at providing earlier access to promising new treatments, including gene therapies, when further data is needed for routine commissioning.

You may also be interested in...



England’s Innovative Medicines Fund To Put Spotlight On Rare Disease Treatments

While the much-anticipated Innovative Medicines Fund is likely to benefit rare diseases in particular, other products must gain too.

Flexibility Is Key To Making England’s Innovative Medicines Fund Work

Stakeholders are calling for NHS England and NHS Improvement (NHSE&I) and the health technology assessment body NICE to bring more flexibility into England’s new Innovative Medicines Fund, which is due for launch later in 2021.

Expectations Are High But What Precisely Will England’s New IMF Deliver?

The Innovative Medicines Fund, due for launch in England later this year, may provide industry with an opportunity to hold key public bodies to account.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS144675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel